Atreca (OTC: BCEL)
Some price data may be temporarily unavailable.
Atreca Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Atreca Company Info
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.
News & Analysis
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March
These three clinical-stage biotechs are all bargains after last month's marketwide downturn.
2 Biotech Stocks Poised for Jaw-Dropping Gains
These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.